Patheon NV (PTHN)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
James C. Mullen
Employees:
9,100
EVERT VAN DE BEEKSTRAAT 104, AMSTERDAM SCHIPHOL, NETHERLANDS 1118 CN
31 (20) 622-3243

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Patheon NV engages in the provsion of pharmaceutical development and manufacturing services. It provides active pharmaceutical ingredient, or API, and finished drug product services to customers, from formulation development to clinical and commercial scale manufacturing, packaging, and lifecycle management. The company was founded on December 24, 2013 and is headquartered in Amsterdam, Netherlands.

Data derived from most recent annual or quarterly report
Market Cap 5.077 Billion Shares Outstanding145.136 Million Avg 30-day Volume 142.551 Thousand
P/E Ratio36.1769 Dividend Yield0.0 EPS-0.34
Price to Revenue2.0362 Debt to Equity-7.394 EBITDA367.4 Million
Price to Book Value0.0 Operating Margin10.2069 Enterprise Value5.921 Billion
Current Ratio1.655 EPS Growth0 Quick Ratio0.847
1 Yr BETA 0.8778 52-week High/Low 0.0 / Profit Margin5.6286
Operating Cash Flow Growth0.0 Free Cash Flow to Firm (FCFF) TTM 0 Free Cash Flow to Equity (FCFE) TTM800.63 Million
Altman Z-Score1.5117
View SEC Filings from PTHN instead.

View recent insider trading info

Patheon NV YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PTHN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PTHN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2017-08-31 by LAGARDE MICHEL
  • 4: filed on 2017-08-31 by WILSON DEAN FREDERICK
  • 4: filed on 2017-08-31 by UTIGER LUKAS
  • 4: filed on 2017-08-31 by TORRES RAUL CARDONA
  • 4: filed on 2017-08-31 by SHERBET ERIC
  • 4: filed on 2017-08-31 by SCHNEIER CRAIG ERIC
  • 4: filed on 2017-08-31 by NEW REBECCA HOLLAND
  • 4: filed on 2017-08-31 by NEGRON FRANCISCO R.
  • 4: filed on 2017-08-31 by MULLEN JAMES C
  • 4: filed on 2017-08-31 by LEHMANN MICHAEL J.

    • Events (8k)

  • 8-K: filed on 2017-09-05:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-22:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-02:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2017-07-20:
    Item 8.01: Other Events
  • 8-K: filed on 2017-07-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-06-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LEVY PAUL S

    • Director
    		 No longer subject to file 2017-08-29 0

    KONINKLIJKE DSM N.V.

    • 10% Owner
    		 0 2017-08-29 0

    COTTIER GILLES PRESIDENT, PHARMA DEV SVCS

    • Officer
    		 No longer subject to file 2017-08-29 0

    HOOGASIAN SETH H

    • Director
    		 0 2017-08-29 0

    HASLER HANS PETER

    • Director
    		 No longer subject to file 2017-08-29 0

    MULLEN JAMES C CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 No longer subject to file 2017-08-29 0

    SCHNEIER CRAIG ERIC EVP AND CHIEF TALENT OFFICER

    • Officer
    		 No longer subject to file 2017-08-29 0

    DALEY PAMELA

    • Director
    		 No longer subject to file 2017-08-29 0

    MCMULLEN JEFFREY P

    • Director
    		 No longer subject to file 2017-08-29 0

    HAYES WILLIAM B

    • Director
    		 No longer subject to file 2017-08-29 0

    GRANT STUART EVP AND CFO

    • Officer
    		 No longer subject to file 2017-08-29 0

    LEHMANN MICHAEL J. EVP, GLOBAL SALES AND MKTNG

    • Officer
    		 No longer subject to file 2017-08-29 0

    WILSON DEAN FREDERICK CHIEF ACCOUNTING OFFICER

    • Officer
    		 No longer subject to file 2017-08-29 0

    JLL ASSOCIATES G.P. V (PATHEON), LTD.

    JLL PATHEON CO-INVESTMENT FUND, L.P.

    JLL ASSOCIATES V (PATHEON), L.P.

    JLL PARTNERS FUND VI (PATHEON), L.P.

    • 10% Owner
    		 No longer subject to file 2017-08-29 0

    LAGARDE MICHEL PRESIDENT

    • Officer
    		 No longer subject to file 2017-08-29 0

    NEW REBECCA HOLLAND EVP, ENTERPRISE OPERATIONS

    • Officer
    		 No longer subject to file 2017-08-29 0

    GILL HARRY R III SVP, QUALITY/CONTINUOUS IMPRVT

    • Officer
    		 No longer subject to file 2017-08-29 0

    COGUT CHARLES I

    • Director
    		 No longer subject to file 2017-08-29 0

    DURBIN PATRICK M

    • Director
    		 0 2017-08-29 0

    PISANO GARY P.

    • Director
    		 No longer subject to file 2017-08-29 0

    SHERBET ERIC GENERAL COUNSEL AND SECRETARY

    • Officer
    		 No longer subject to file 2017-08-29 0

    UTIGER LUKAS PRESIDENT, DRUG SUBSTANCE SVCS

    • Officer
    		 No longer subject to file 2017-08-29 0

    NEGRON FRANCISCO R. PRESIDENT, DRUG PRODUCT SVCS

    • Officer
    		 No longer subject to file 2017-08-29 0

    TANDA STEPHAN B.

    • Director
    		 No longer subject to file 2017-08-29 0

    EYKERMAN PHILIP

    • Director
    		 No longer subject to file 2017-08-29 0

    TORRES RAUL CARDONA SVP, QUALITY

    • Officer
    		 No longer subject to file 2017-08-29 0

    SMITH ANTHONY HUGH

    • Director
    		 0 2017-08-29 0

    LADIWALA SHIRAZ SHABANALI

    • Director
    		 0 2017-08-29 0

    SOS JOHN FAROUK

    • Director
    		 0 2017-08-29 0

    LYTTON MICHAEL EVP, CORP DEVELOPMENT & STRTGY

    • Officer
    		 386,292 2016-07-20 0

    AGROSKIN DANIEL

    • Director
    		 0 2016-07-20 0

    JLL ASSOCIATES G.P. V (PATHEON), LTD.

    JLL/DELTA PATHEON GP, LTD.

    JLL/DELTA PATHEON HOLDINGS, L.P.

    JLL/PATHEON CO-INVESTMENT FUND, L.P.

    PATHEON HOLDCO COOPERATIEF U.A.

    JLL ASSOCIATES V (PATHEON), L.P.

    JLL PARTNERS FUND V (NEW PATHEON), L.P.

    JLL PARTNERS FUND VI (PATHEON), L.P.

    • 10% Owner
    		 61,781,814 2016-07-20 0

    WELSH HUGH C.

    • Director
    		 0 2016-07-20 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments